Cyclacel Pharmaceuticals jumps on sapacitabine patent news

Cyclacel Pharmaceuticals (CYCC +7.8%) rallies on heavy volume.

The company says the U.S. Patent Office has "issued two patents extending the exclusivity of sapacitabine."

The first patent covers "methods of treating cancer comprising sapacitabine together with DNA methyltransferase inhibitors," while the second covers "methods of use for sapacitabine for the treatment of AML and MDS." (PR)

Comments (1)
  • Insiderz
    , contributor
    Comments (100) | Send Message
    do we get some Sapacitabine data when the ash abstracts come out on 11/7?
    5 Nov 2013, 02:54 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs